RAPT Therapeutics (RAPT) Cash & Current Investments (2020 - 2024)
Historic Cash & Current Investments for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $97.9 million.
- Therapeutics' Cash & Current Investments fell 4701.45% to $97.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $97.9 million, marking a year-over-year decrease of 4701.45%. This contributed to the annual value of $158.9 million for FY2023, which is 3621.74% down from last year.
- As of Q3 2024, Therapeutics' Cash & Current Investments stood at $97.9 million, which was down 4701.45% from $114.8 million recorded in Q2 2024.
- Therapeutics' Cash & Current Investments' 5-year high stood at $249.1 million during Q4 2022, with a 5-year trough of $97.9 million in Q3 2024.
- Its 5-year average for Cash & Current Investments is $167.7 million, with a median of $173.0 million in 2022.
- As far as peak fluctuations go, Therapeutics' Cash & Current Investments surged by 7581.04% in 2022, and later plummeted by 4701.45% in 2024.
- Therapeutics' Cash & Current Investments (Quarter) stood at $111.5 million in 2020, then soared by 70.08% to $189.7 million in 2021, then skyrocketed by 31.33% to $249.1 million in 2022, then plummeted by 36.22% to $158.9 million in 2023, then tumbled by 38.37% to $97.9 million in 2024.
- Its Cash & Current Investments was $97.9 million in Q3 2024, compared to $114.8 million in Q2 2024 and $141.6 million in Q1 2024.